IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
225 hedge funds and large institutions have $3.12B invested in IVERIC bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 88 increasing their positions, 62 reducing their positions, and 38 closing their positions.
90% more funds holding in top 10
Funds holding in top 10: 10 → 19 (+9)
42% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 62
37% more call options, than puts
Call options by funds: $35.3M | Put options by funds: $25.6M
37% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 38
35% more capital invested
Capital invested by funds: $2.31B → $3.12B (+$805M)
6% more funds holding
Funds holding: 213 → 225 (+12)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$86.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$50.4M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$39.9M |
| 4 |
BlackRock
New York
|
+$34.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.8M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$121M |
| 2 |
RI
RTW Investments
New York
|
-$59.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$49.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$17.9M |
| 5 |
DM
Deerfield Management
New York
|
-$17.5M |
ISEE Hedge Fund Activity: Q4 2022 in Review
225 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q4 2022, worth a combined $3.12B — up 35% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new ISEE positions and 38 closed out — a net gain of 14 holders — while 88 added to existing stakes and 62 trimmed.
The largest buyer was Vanguard Group, adding an estimated $86.1M. The largest seller was Janus Henderson Group, cutting an estimated $121M.
- 225 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q4 2022, up from 213 in Q3 2022.
- Funds reported $3.12B of IVERIC bio, Inc. Common Stock stock for Q4 2022, up 35% quarter-over-quarter.
- 52 funds opened new IVERIC bio, Inc. Common Stock positions in Q4 2022 and 38 closed out, a net change of +14 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q4 2022 was Vanguard Group, an estimated $86.1M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q4 2022 was Janus Henderson Group, an estimated $121M sold.
Based on aggregated 13F filings for Q4 2022.